Stockreport

Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF positive Phase 1b/2 results from its ongoing TUPELO trial evaluating REC-4881, which is a first-in-class allosteric MEK1/2 inhibitor for Familial Adenomatous Polyposis/F [Read more]